The differential response to immune checkpoint inhibitors in colorectal and endometrial cancer patients according to different mismatch repair alterations

Authors:

Moh’d M. Khushman, Michael Driscoll Toboni, Jia Zeng, Joanne Xiu, Upender Manne, Alex Farrell, Bassel El-Rayes, Emil Lou, Anthony Frank Shields, Philip Agop Philip, Mohamed E. Salem, Jim Abraham, David Spetzler, John Marshall, Priya Jayachandran, Michael J. Hall, Heinz-Josef Lenz, Wolfgang Michael Korn, Matthew A. Powell

Key Finding:

  • In colorectal cancer patients, median overall survival and median overall survival in response to immune checkpoint inhibition is longer in patients with intact MLH1 and PMS2 and co-loss of MSH2 and MSH6 (MutS) versus co-loss of MLH1 and PMS2 and intact MSH2 and MSH6 (MutL). 
Download Publication